Personalized Treatment Optimization for Kidney Health in Type 2 Diabetes: A Remote Trial with Empagliflozin and Finerenone

Phase 1

• Conditions: Albuminuria, Type 2 diabetes; MedDRA version: 21.1Level: LLTClassification code: 10045242Term: Type II diabetes mellitus Class: 10027433; MedDRA version: 20.0Level: PTClassification code: 10001580Term: Albuminuria Class: 100000004857; MedDRA version: 21.1Level: LLTClassification code: 10045250Term: Type II diabetes mellitus with renal manifestations Class: 10038359; Therapeutic area: Diseases [C] - Hormonal diseases [C19]; Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]; Therapeutic area: Diseases [C] - Pathological Conditions, Signs and Symptoms [C23]

• Registration Number: CTIS2023-508585-15-00
• Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-02-06
• Last Update Posted: 22 July 2024

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

Age =18 years, Diagnosis of type 2 diabetes, UACR >4.5 mg/mmol (>40 mg/g) and =300 mg/mmol (=2655 mg/g), eGFR =25 mL/min/1.73m^2, On a stable dose of an ACE inhibitor/ARB if tolerated, Willing to sign informed consent, Proficiency in the Dutch language

Exclusion Criteria

Diagnosis of type 1 diabetes, Unstable or rapidly progressing renal disease, Active malignancy, Suggestive evidence of adrenal insufficiency, History of severe hypersensitivity or contraindications to any SGLT2 inhibitor or MRA, Uncontrolled arterial hypertension (mean sitting systolic blood pressure =180 mmHg or diastolic blood pressure =110 mmHg), Any medication, surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of medications including, but not limited to any of the following: History of active inflammatory bowel disease within the last 6 months; Major gastrointestinal tract surgery as decided by the physician; Pancreatitis within the last 6 months; Gastrointestinal ulcers and/or bleeding within the last 6 months; Evidence of urinary obstruction or difficulty in voiding at screening, Participation in any clinical trial within 3 months prior to initial dosing, Donation or loss of =400 mL of blood within 8 weeks prior to initial dosing, Confirmed lactose intolerance demonstrated with a lactose intolerance test, History of drug or alcohol abuse within the 12 months prior to dosing, or evidence of such abuse as indicated by the laboratory assays conducted during screening or according to investigator’s assessment, Already being treated with any SGLT2 inhibitor or MRA, History of noncompliance to medical regimens or unwillingness to comply with the study protocol, Any surgical or medical condition, which in the opinion of the investigator, may place the patient at higher risk from his/her participation in the study, or is likely to prevent the patient from complying with the requirements of the study or completing the study, Women of childbearing potential (WOCBP): WOCBP who are unwilling or unable to use an acceptable method of contraception to avoid pregnancy throughout the study and for up to 4 weeks after the last dose of the study drug in such a manner the risk of pregnancy is minimized; WOCBP must have a negative serum or urine pregnancy test result (minimum sensitivity 25 IU/L or equivalent of HCG) at screening. WOCBP comprises women who have experienced menarche and who have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or who are not post-menopausal. The following women are NOT considered as WOCBP: Women using the following methods to prevent pregnancy: oral contraceptives, other hormonal contraceptives (vaginal products, skin patches, or implanted or injectable products), or mechanical products such as intrauterine devices or barrier methods (diaphragm, condoms, spermicides); Women who are practicing abstinence; Women who have a partner who is sterile (e.g. due to vasectomy). Post-menopause is defined as: Women who have had amenorrhea for >12 consecutive months (without another cause) and who have a documented serum follicle-stimulating hormone (FSH) level >35 mIU/mL; Women who have irregular menstrual periods and a documented serum FSH level >35 mIU/mL; Women who are taking hormone replacement therapy (HRT), Unable to monitor blood pressure or body weight or handle digital technologies, Heart failure NYHA Class II to IV requiring MRA treatment, Acute coronary syndrome event within 6 months, Serum potassium >5 mmol/L after repeated measurement, Evidence of severe hepatic impairment determined by any of one: ALT or AST values exceeding 3 times ULN, a history of hepatic encephalopathy, a history

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified